Chamomile as Medicine for Prostate cancer

洋甘菊作为治疗前列腺癌的药物

基本信息

  • 批准号:
    7285702
  • 负责人:
  • 金额:
    $ 26.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-09-15 至 2010-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Epidemiological studies and clinical observations suggest that persistent chronic inflammation is important in prostate carcinogenesis. The reactive oxygen and nitrogen species released from inflammatory cells induce oxidative stress in the proliferating epithelium that could directly interact with DNA to produce permanent genomic alterations and/or play critical role as regulatory mediators in signaling processes by activating transcription factor complex, NFkappaB. Members of the Rel/NF-kappaB family control important network of genes that influence cell proliferation, inflammation, cellular adhesion, apoptosis and adaptive responses to changes in cellular redox balance. Aberrant NFkappaB activation has been implicated in the pathogenesis of several human malignancies. Our recent studies (Neoplasia Vol.6 No.4, 2004) have shown that NF-kappaB/p65 is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Based on these interesting findings we suggest NF-kappaB signaling pathway as a key molecular target for the development of preventive and/or therapeutic strategies against prostate cancer. The present proposal capitalizes on these novel findings and is designed to investigate the antiinflammatory, antioxidant and cancer chemopreventive potential of chamomile, a common herb used as folk medicine, by targeting NF-kappaB signaling pathway. Recent interest in the development of chamomile as complementary and alternative medicine (CAM) for prostate cancer is due to its anti-inflammatory, antioxidant and mild sedative properties. Chamomile is one of the most popular herbs consumed in the form of tea equivalent to over one million cups per day. The specific aims 1-4 will investigate the molecular mechanism(s) of chamomile that can directly lead to inhibition of NF-kappaB and its responsive genes important in prostate cancer progression (cyclin D1, Bcl2, BclxL, IL-6, IL-8, MMP- 9, and PAR4); and/or indirectly through i) ROS production, ii) transcriptional regulation of inflammatory genes (COX-2 and NOS-2), iii) transactivation of gamma-glutamylcysteine synthetase promoter, and iv) Nrf2/ARE-dependent detoxification in both androgen sensitive- and insensitive- human prostate carcinoma cells. We will also investigate how chamomile can mediate these effects through down-regulation of NF-kappaB by analyzing levels and activity of key kinase molecules and associated mechanisms that are involved in the NF-kappaB signaling pathway. Moreover, we will employ genetic (over-expression and suppression.techniques) and pharmacological (inhibitors) approaches to delineate whether the effects of chamomile are directly mediated by the down regulation of NF-kappaB. These results will be compared to those obtained from normal human prostate epithelial cells. Additionally, we also propose to test the cancer chemopreventive potential of chamomile in a well established transgenic mouse model, TRAMP that exhibit significantly higher constitutive NF-kappaB/p65 expression during prostate cancer progression. Completion of the proposed studies will provide a 'head start' to initiate clinical trials in prostate cancer patients and/or high-risk individuals.
描述(由申请人提供):流行病学研究和临床观察表明,持续的慢性炎症在前列腺癌发生中很重要。从炎症细胞释放的活性氧和氮物质诱导增殖上皮中的氧化应激,其可以直接与DNA相互作用以产生永久性基因组改变和/或通过激活转录因子复合物NF κ B在信号传导过程中作为调节介质发挥关键作用。Rel/NF-κ B家族成员控制影响细胞增殖、炎症、细胞粘附、凋亡和对细胞氧化还原平衡变化的适应性反应的重要基因网络。异常NF κ B活化与几种人类恶性肿瘤的发病机制有关。我们最近的研究(Neoplasia Vol.6 No.4,2004)表明NF-κ B/p65在人前列腺癌中被组成性激活并与疾病进展相关。基于这些有趣的发现,我们建议NF-κ B信号通路作为预防和/或治疗前列腺癌的策略的发展的关键分子靶点。本提案利用这些新的发现,旨在通过靶向NF-κ B信号通路来研究洋甘菊(一种用作民间药物的常见草药)的抗氧化,抗氧化和癌症化学预防潜力。最近对洋甘菊作为前列腺癌的补充和替代药物(CAM)的开发感兴趣是由于其抗炎,抗氧化和温和的镇静特性。洋甘菊是最受欢迎的草药之一,每天以茶的形式消耗超过一百万杯。具体目标1-4将研究甘菊的分子机制,其可直接导致抑制NF-κ B及其在前列腺癌进展中重要的应答基因(细胞周期蛋白D1、Bcl 2、BclxL、IL-6、IL-8、MMP- 9和PAR 4);和/或间接通过i)活性氧产生,ii)炎症基因的转录调节(考克斯-2和NOS-2),iii)γ-谷氨酰半胱氨酸合成酶启动子的反式激活,和iv)在雄激素敏感和不敏感的人前列腺癌细胞中Nrf 2/ARE依赖性解毒。我们还将通过分析参与NF-κ B信号通路的关键激酶分子和相关机制的水平和活性,研究洋甘菊如何通过下调NF-κ B来介导这些效应。此外,我们将采用遗传(过表达和抑制技术)和药理学(抑制剂)方法来描述洋甘菊的作用是否直接由NF-κ B的下调介导。将这些结果与从正常人前列腺上皮细胞获得的结果进行比较。此外,我们还建议在一个完善的转基因小鼠模型中测试洋甘菊的癌症化学预防潜力,TRAMP在前列腺癌进展期间表现出显着更高的组成型NF-κ B/p65表达。完成拟议的研究将为在前列腺癌患者和/或高危人群中开展临床试验提供一个“良好开端”。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SANJAY GUPTA其他文献

SANJAY GUPTA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SANJAY GUPTA', 18)}}的其他基金

TIMP3: A Molecular Target of Green Tea Polyphenols
TIMP3:绿茶多酚的分子靶点
  • 批准号:
    9099803
  • 财政年份:
    2015
  • 资助金额:
    $ 26.55万
  • 项目类别:
Targeting EZH2 in Prostate Cancer by Luteolin
通过木犀草素靶向前列腺癌中的 EZH2
  • 批准号:
    8816655
  • 财政年份:
    2015
  • 资助金额:
    $ 26.55万
  • 项目类别:
TIMP3: A Molecular Target of Green Tea Polyphenols
TIMP3:绿茶多酚的分子靶标
  • 批准号:
    8852245
  • 财政年份:
    2015
  • 资助金额:
    $ 26.55万
  • 项目类别:
Prevention of Metastasis by Green Tea Polyphenols
绿茶多酚预防转移
  • 批准号:
    8887104
  • 财政年份:
    2014
  • 资助金额:
    $ 26.55万
  • 项目类别:
Prevention of Metastasis by Green Tea Polyphenols
绿茶多酚预防转移
  • 批准号:
    8786621
  • 财政年份:
    2014
  • 资助金额:
    $ 26.55万
  • 项目类别:
Molecular Mechanisms of GSTP1 Reactivation by Green Tea Polyphenols
绿茶多酚重新激活 GSTP1 的分子机制
  • 批准号:
    7458816
  • 财政年份:
    2007
  • 资助金额:
    $ 26.55万
  • 项目类别:
Molecular Mechanisms of GSTP1 Reactivation by Green Tea Polyphenols
绿茶多酚重新激活 GSTP1 的分子机制
  • 批准号:
    8070446
  • 财政年份:
    2007
  • 资助金额:
    $ 26.55万
  • 项目类别:
Molecular Mechanisms of GSTP1 Reactivation by Green Tea Polyphenols
绿茶多酚重新激活 GSTP1 的分子机制
  • 批准号:
    7627358
  • 财政年份:
    2007
  • 资助金额:
    $ 26.55万
  • 项目类别:
Molecular Mechanisms of GSTP1 Reactivation by Green Tea Polyphenols
绿茶多酚重新激活 GSTP1 的分子机制
  • 批准号:
    7825491
  • 财政年份:
    2007
  • 资助金额:
    $ 26.55万
  • 项目类别:
Molecular Mechanisms of GSTP1 Reactivation by Green Tea Polyphenols
绿茶多酚重新激活 GSTP1 的分子机制
  • 批准号:
    7262072
  • 财政年份:
    2007
  • 资助金额:
    $ 26.55万
  • 项目类别:

相似国自然基金

大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
  • 批准号:
    30840003
  • 批准年份:
    2008
  • 资助金额:
    12.0 万元
  • 项目类别:
    专项基金项目

相似海外基金

Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
  • 批准号:
    478914
  • 财政年份:
    2023
  • 资助金额:
    $ 26.55万
  • 项目类别:
    Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
  • 批准号:
    23K14913
  • 财政年份:
    2023
  • 资助金额:
    $ 26.55万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
  • 批准号:
    23K15035
  • 财政年份:
    2023
  • 资助金额:
    $ 26.55万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
  • 批准号:
    10442874
  • 财政年份:
    2023
  • 资助金额:
    $ 26.55万
  • 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
  • 批准号:
    10657069
  • 财政年份:
    2023
  • 资助金额:
    $ 26.55万
  • 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
  • 批准号:
    23K08326
  • 财政年份:
    2023
  • 资助金额:
    $ 26.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
  • 批准号:
    23K14614
  • 财政年份:
    2023
  • 资助金额:
    $ 26.55万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
  • 批准号:
    23K15075
  • 财政年份:
    2023
  • 资助金额:
    $ 26.55万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
  • 批准号:
    23H02698
  • 财政年份:
    2023
  • 资助金额:
    $ 26.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
  • 批准号:
    10743611
  • 财政年份:
    2023
  • 资助金额:
    $ 26.55万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了